Drug Maker Named In Investor Suit Over I&I Drug Financial Success Estimates
NEWARK, N.J. — A biotechnology company and three of its former senior executives violated federal securities laws by issuing a series of misrepresentations regarding the expected financial windfall of two new...To view the full article, register now.
Already a subscriber? Click here to view full article